Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MEDS by emailGet an email when MEDS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MEDS, unsubscribe in one click. Privacy
📣 What MEDS Says Is Next
Second Half 2026 · “Interim co-CEO Gerald Commissiong featured on Fox Business together with NFL Legend Emmitt Smith to discuss NFLAH support for Health Lives Here Expected Remaining Second Half 2026 Milestones”
Company press release, Aug 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MEDS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MEDS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.